not known

Client attended for discussion regarding current use of Mounjaro (tirzepatide); client reports injecting less frequently than the licensed once-weekly schedule and using a so-called “golden dose” regimen, which is unlicensed and outside prescribing guidance. Client reports treatment outcomes to date have been successful and denies experiencing any side effects or adverse reactions. Medication use, dosing schedule, and indication were discussed, and client confirmed awareness that this method is not prescribed, approved, or supported by clinical evidence. The licensed once-weekly administration of tirzepatide and the risks associated with non-standard dosing were explained, including reduced or unpredictable efficacy, altered side-effect profile, difficulty monitoring safety, and lack of medical oversight. The importance of ongoing treatment to maintain achieved results was discussed, including that discontinuation or inconsistent use may lead to loss of therapeutic benefit. Client demonstrated capacity, verbalised understanding